Follow
International Journal of Current Microbiology and Applied Sciences (IJCMAS)
IJCMAS is now DOI (CrossRef) registered Research Journal. The DOIs are assigned to all published IJCMAS Articles.
Index Copernicus ICI Journals Master List 2022 - IJCMAS--ICV 2022: 95.28 For more details click here
National Academy of Agricultural Sciences (NAAS) : NAAS Score: *5.38 (2020) [Effective from January 1, 2020] For more details click here

Login as a Reviewer


See Guidelines to Authors
Current Issues
Download Publication Certificate

Original Research Articles                      Volume : 10, Issue:6, June, 2021

PRINT ISSN : 2319-7692
Online ISSN : 2319-7706
Issues : 12 per year
Publisher : Excellent Publishers
Email : editorijcmas@gmail.com /
submit@ijcmas.com
Editor-in-chief: Dr.M.Prakash
Index Copernicus ICV 2018: 95.39
NAAS RATING 2020: 5.38

Int.J.Curr.Microbiol.App.Sci.2021.10(6): 555-565
DOI: https://doi.org/10.20546/ijcmas.2021.1006.061


Adverse Event following Immunization (AEFI) and COVID-19 Vaccination: A Review
Sharique Ahmad1*, Shivani Singh1, Saeeda Wasim2 and Silky Rai1
1Department of Pathology, Era's Lucknow Medical College and Hospital, Era University, Lucknow, Uttar Pradesh – 226003, India
2Consultant, Nova IVF Fertility, Hazratganj, Lucknow, U.P. - 226001, India
*Corresponding author
Abstract:

Adverse event following immunization (AEFI) is basically an event of unexpected medical emergency occurring after vaccination on immunization without any causal association with vaccination. It can be any unintended, abnormal laboratory finding or anything. At the time of vaccination, there are many reasons like improper way of vaccination by health worker or quality defect of any specific vaccine. All these are the unintentional events which can lead to an adverse event in any individual. As recognition of adverse events resulted due to vaccine can be both before and after licensure. Before includes vaccination on candidate trials for evaluation of efficacy and protection. These trials mainly included various individual and can identify frequent adverse events involved after vaccination. Although, adverse events which are very rare cannot be observed during pre-licensure testing and can only be observed at the time of marketing surveillance when it come in use at wide scale. Post-marketing surveillance became complex due to the events resulting after vaccination are not mainly caused through administration of vaccine. Establishment of AEFI resulting due to any vaccination program requires careful assessment of few factors like laboratory handling, clinical factors and epidemiological factors. Its cause and effect can be enhanced by determination of rate of illness following immunization which is greater than illness in absence of vaccination. Consequently, significant attention must be required for interpreting adverse event reports associated temporarily with causality of vaccination. Currently, two complementary post-marketing system of surveillance for vaccines in United States are present. In 1978, a monitoring system was established for adverse event following immunization (AEFI) for collecting reports for public sector concerning adverse events following immunization. These reports were made from the data collected from the person who is vaccinated within 30 days of receiving vaccine. There had been some specific knowledge associated with vaccination and its adverse events like anaphylaxis associated with hepatitis B, measles thrombocytopenia and various other vaccines associated adverse events were observed which are normal but in few cases, anaphylaxis and spread of disease in immunocompromised individuals can lead to death. So, at the time of vaccination, care should be taken in assessing individuals medical history.


Keywords: Adverse event following immunization (AEFI), Vaccination, Anaphylaxis, Covid-19

Download this article as Download

How to cite this article:

Sharique Ahmad, Shivani Singh, Saeeda Wasim and Silky Rai. 2021. Adverse Event following Immunization (AEFI) and COVID-19 Vaccination: A Review.
Int.J.Curr.Microbiol.App.Sci. 10(6): 555-565. doi: https://doi.org/10.20546/ijcmas.2021.1006.061
Copyright: This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike license.

Citations